Zoledronate

Zoledronate (Zometa™) is exclusively administered intravenously.

Its indications are :

• severe malignant hypercalcaemia,
  
• stage III multiple myeloma with one or many bone lesion(s),
  
• palliative treatment of malignant osteolysis, with or without hypercalcaemia, in addition to specific tumour treatment,
  

Pyrophosphate	Zoledronate

Since it is slowly eliminated from the blood, the usual dosage is relatively low (about 4 to 8 mg per cure which can be renewed every 4 weeks). In malignant hypercalcaemia, strict monitoring is required. Infusion is short (about 30 minutes).

During infusion, fever may be observed (delayed fever can also occur ) as well as flu-like syndrome, local reactions, bone pains, myalgias. All of these side effects are generally mild.